161 results about "Hiv infected" patented technology

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed is a second method of treating HIV in a mammal involving administering to the mammal an effective amount of therapeutic cells expressing a membrane-bound, proteinaceous chimeric receptor comprising an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Disclosed is a method of directing a cellular immune response against an HIV-infected cell in a mammal involving administering to the mammal an effective amount of therapeutic cells which express a membrane-bound, proteinaceous chimeric receptor comprising (a) an extracellular portion which includes a fragment of CD4 which is capable of specifically recognizing and binding the HIV-infected cell but which does not mediate HIV infection and (b) an intracellular portion which is capable of signalling the therapeutic cell to destroy the receptor-bound HIV-infected cell. Also disclosed are cells which express the chimeric receptors and DNA and vectors encoding the chimeric receptors.

Methods and compositions for treatment of human immunodeficiency virus (HIV) infections have been developed which dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibit infection of cells by HIV. Pushing latent HIV into active infections with hindrance of cell infection by the reactivated HIV can substantially reduce the number of cells infected with HIV and the viral load of HIV, which is not achieved using just the combination of ART and compounds which activate latent HIV. The methods involve administering to an HIV-infected subject three or more compounds which collectively dampen immune activation with a bias more on the CD4 T cells relative to the CD8 T cell response, inhibit HIV replication, reactivate latent HIV, and inhibiting infection of CD4 T cells by HIV.

The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

Provided is a pharmaceutical composition comprising a solution comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Also provided is a synthetic peptide-containing pharmaceutical composition as a unit dose comprising an aqueous formulation comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Further provided is a method of treating HIV infection by administering to an HIV-infected individual a pharmaceutical composition according to the present invention.

Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.

A chimeric protein compound for durable and efficient suppression to different chemotactic factor receptors, its nucleic acid sequence, and the process for preparing and testing its products are disclosed. It can be used to prevent and cure HIV infection, tumor transfer, tissue transplant rejection and self immunopathy. Its advantages are high durability, broad spectrum, and high selectivity.

The invention relates to the field of medicine, in particular to a composition for activating an HIV latent virus and application thereof. The composition consists of a monoclonal antibody drug, a histone deacetylase inhibitor and a PKC activator, wherein the monoclonal antibody drug is selected from an anti-human CD3 monoclonal antibody and an anti-human CD28 monoclonal antibody, the histone deacetylase inhibitor is selected from at least one of vorinostat and valproic acid, and a PKC activator is 12-deoxyphorbol-13-acetic acid (Prostratin). The main obstacle to cure the HIV is that the HIV establishes a hidden 'reservoir' of viruses in the body at the very early stage of infection. The composition has the effect of significantly activating latent HIV-infected CD4+ T cells, can activate the HIV latent virus simultaneously at the cellular level, the chromatin level and the HIV-specific transcription factor level, can fully activate the HIV pre-virus in the resting CD4+ T cells withoutsignificant cytotoxic side effects and is a necessary way to HIV functional healing.

A pharmaceutical composition comprising (1S,cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, in an amount which achieves antiviral efficacy, a process for the preparation of such a composition, and a method of inhibiting human immunodeficiency virus (HIV) which comprises administering such a composition to an HIV infected patient is disclosed.

The present invention provides an improved method for eliciting a therapeutic immune response in an individual infected with human immunodeficiency virus (“HIV”). The method comprises administering an adenoviral vaccine composition expressing an HIV antigen to an individual with controlled viremia. Immunization of infected individuals in this manner elicits a cellular-mediated immune response against the virus that is significant both in the level of the response and the breadth of the response. The therapeutic immune response that ensues is capable of effectively maintaining low titers of virus and, thus, offers the prospect of reducing individual dependency on antiviral therapy.

This invention is in the area of molecular biology/virology and presents oligonucleotides with nucleotide-sequences specific for SI HIV-1 strains. These oligonucleotides may be used for in vitro determination of biological phenotype of HIV-1 strain in biological material from HIV-infected individuals by a number of techniques such as Southern and Northern blot analysis, PCR, NASBA, in situ hybridization, branched DNA hybridization, heteroduplex tracing hybridization and liquid hybridizations. HIV-1 phenotyping may i.e. be used as a diagnostic marker for disease progression or for testing efficacy of antiviral therapy.

The present invention provides methods and devices for predicting whether a HIV variant will be resistant to an antiviral drug based on the variant's genotype. In one aspect, methods are provided comprising determining whether a combination of protease inhibitor resistance mutations meet certain conditions, as disclosed herein, thereby assessing the effectiveness of ritonavir-boosted indinavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV resistance are provided.

The invention provides a screening system of HIV infected cell. A reporter protein gene is divided into a reporter gene N-end and a reporter gene C-end, wherein the reporter gene N-end and dnae-N which has the protein splicing function and is the part of DnaE intein N-end gene are blended to form an expression vector I; and the reporter gene C-end and dnae-C which has the protein splicing functionand is the part of DnaE intein C-end gene are blended to form an expression vector II. The two expression vectors respectively transfect an HEK293 cell or a CHO cell containing chemotactic factors and CD4 protein or containing envelope protein Env of HIV, and establish stable expression cell stains. When the two strains of stable cells are cultured mixedly, the cells are blended, thus promoting DnaE-C and DnaE-N to mutually contact and act; while the combined action of DnaE-N and DnaE-C connects the reporter protein N-end and the reporter protein C-end into one complete reporter protein, andfinally, the blending degree can be learned by the protein activity of a test report.

The invention provides malania oleifera lectin and a method for preparing the same. The method comprises the following steps: grinding malania oleifera, stirring and socking the ground malania oleifera into cold water, grading and precipitating by using ammonium sulfate, ultrafiltering to remove salt, concentrating, carrying out ion exchange chromatography, purifying, ultrafiltering to remove salt, concentrating, freezing and drying to obtain the refined malania oleifera lectin. The prepared malania oleifera lectin has the molecular weight of about 60kd, the electrophoresis purity of above 90% and the potency of 1:10<5> or more, namely the HIV infected cell (inhibition concentration 50) IC50 of 1:10<5>, can agglutinate the red blood cells of a rabbit, a pig, a chicken, a duck and a mouse and can be used for preventing HIV infection.

The invention discloses a medicinal composition for treating acquired immune deficiency syndrome (Aids) as well as a preparation method, quality control method and application of the medicinal composition. The raw materials of the medicinal composition comprise cooked monkshood, herba epimedii, dried ginger, liquorice, ginseng, the root of red-rooted salvia, giant knot weed, Poria cocos, golden cypress and Scutellaria baicalensis. Experimental data indicate that the medicinal composition preparation disclosed by the invention has Aids treating function on Aids model monkeys derived from rhesus monkeys infected by monkey Aids Virus, based on the curative effect on the Aids monkey models adaptive to Aids animal models, the medicinal composition preparation has the application of treating human Aids; after being given to HIV infected persons or Aids patients, the medicinal composition preparation can relieve disease, i stabilize or improvethe CD4+T lymphocyte count level of the HIV infected persons or the Aids patients, relieve clinical clinical symptoms and improve survival quality.

The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as CDM-Hs, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by introducing cytotoxic moieties to gp120-expressing cells, thereby causing cell death and preventing cell infection and spread of HIV. It is shown that CDM-Hs bind to gp120 and gp-120 expressing cells competitively with CD4, and these compounds cause cell death of HIV-infected cells, thereby decreasing viral infectivity. Compounds and methods are described herein.

A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into activated, HIV-infected cells, e.g., activated, HIV-infected macrophage and T-lymphocyte cells. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV virions in an infected individual.